Form 8-K - Current report:
SEC Accession No. 0001193125-25-116071
Filing Date
2025-05-08
Accepted
2025-05-08 17:18:55
Documents
13
Period of Report
2025-05-05
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d60800d8k.htm   iXBRL 8-K 24218
  Complete submission text file 0001193125-25-116071.txt   142045

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA igms-20250505.xsd EX-101.SCH 2834
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE igms-20250505_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE igms-20250505_pre.xml EX-101.PRE 10801
15 EXTRACTED XBRL INSTANCE DOCUMENT d60800d8k_htm.xml XML 3507
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 25927441
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)